Clinical Trials

Cardiol Therapeutics is currently conducting a Phase II open-label pilot study (NCT05494788) to evaluate CardiolRx™ in patients with recurrent pericarditis. The study will measure changes in patient-reported pain and other clinical markers over an 8-week period, with secondary endpoints assessed after 26 weeks of treatment.

Answer last refreshed: 2026-08-18